# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

> **NCT05039619** · PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 40 (estimated)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Placebo
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Acetaminophen/paracetamol
- **DRUG:** Diphenhydramine hydrochloride (HCl)
- **DRUG:** Methylprednisolone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05039619
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-12
- **Primary completion:** 2028-06-15
- **Final completion:** 2030-06-14
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039619, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05039619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*